Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine in Malignant Mesothelioma
NCT00004183Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Nov 2000
- Primary completion
- Dec 2003
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in malignant mesothelioma, sponsored by Cancer and Leukemia Group B. Started Nov 2000; status: completed.
02
Drugs
capecitabine
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT00004183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004183.